# Alendronic acid modified PLGA drug delivery system loaded with 17β-Estradiol and vitamin D3 has anti-osteoporotic effect

**Authors:** Yonghui Wang, Sidi Zhang, Xinrun Ma, Donghao Hu, Junran Liu, Lu Wei, Xue Lei, Yan Hu, Fuyou Li, Yanhong Gao

PMC · DOI: 10.1016/j.mtbio.2026.102789 · 2026-01-12

## TL;DR

A new drug delivery system targets bones to treat osteoporosis safely, avoiding side effects of traditional hormone therapy.

## Contribution

A bone-targeted PLGA nanocarrier modified with alendronic acid co-delivers estradiol and vitamin D3 for safer osteoporosis treatment.

## Key findings

- The nanocarrier significantly improved bone mineral density in ovariectomized mice.
- It reduced endometrial thickening caused by estradiol and showed sustained drug release.
- The combination enhanced osteogenesis via activation of the PI3K/AKT/mTOR signaling pathway.

## Abstract

Postmenopausal osteoporosis caused by estrogen deficiency often requires hormone replacement therapy (HRT), but its systemic side effects limit clinical application. Here, we developed a bone-targeted Poly (lactic-co-glycolic acid) (PLGA) nanocarrier modified with Alendronic acid (ADA) to co-deliver 17β-Estradiol (E2) and Vitamin D3 (VitD3), aiming to enhance efficacy and safety. The ADA-functionalized nanoparticles (E2+VD@PLGAIR780ADA) showed high drug loading (7.2 wt% for E2 and 2.3 wt% for VitD3), sustained release (>90 % over 48 h). In ovariectomized (OVX) mice, targeted delivery significantly improved bone mineral density, restored trabecular structure, and reduced serum bone resorption markers, while markedly alleviating E2-induced endometrial thickening. In vivo imaging confirmed selective bone accumulation. Mechanistically, co-administration of VitD3 and E2 elicits enhanced pro-osteogenic effects by virtue of VitD3-mediated Vitamin D Receptor (VDR) upregulation and amplified E2-induced estrogen receptor (ER) expression, which collectively drive robust activation of the PI3K/AKT/mTOR signaling cascade.This bone-specific nanoplatform offers a promising and safer strategy for osteoporosis therapy beyond conventional HRT.

E2+VD@PLGAIR780ADA targets bones to improve osteogenesis.Image 1

E2+VD@PLGAIR780ADA targets bones to improve osteogenesis.

## Linked entities

- **Proteins:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase)
- **Chemicals:** Alendronic acid (PubChem CID 2088), 17β-Estradiol (PubChem CID 154274), Vitamin D3 (PubChem CID 5280795)
- **Diseases:** osteoporosis (MONDO:0005298)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Vdr (vitamin D (1,25-dihydroxyvitamin D3) receptor) [NCBI Gene 22337] {aka Nr1i1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Esr1 (estrogen receptor 1 (alpha)) [NCBI Gene 13982] {aka ER, ER-alpha, ERa, ERalpha, ESR, Estr}
- **Diseases:** estrogen deficiency (MESH:D056828), osteoporosis (MESH:D010024), osteoporotic (MESH:D058866)
- **Chemicals:** VD@PLGAIR780ADA (-), 17beta-Estradiol (MESH:D004958), PLGA (MESH:D000077182), VitD3 (MESH:D002762), ADA (MESH:D019386)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Figures

17 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12854061/full.md

---
Source: https://tomesphere.com/paper/PMC12854061